Skip to main content

Table 2 Associations of FBXOs expression with clinical manifestations in BC patients (Bc-GenExMiner, v4.4)

From: Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer

Variables No FBXO1 P-value FBXO2 P-value FBXO5 P-value FBXO6 P-value FBXO16 P-value FBXO17 P-value FBXO22 P-value FBXO28 P-value FBXO31 P-value FBXO45 P-value
Age
 ≤ 51 1099 **** p =  .0515 **** p =  .7262 p =  .7978 *** p =  .6565 p =  .6215 ** ****
 > 51 3208         
Nodal status
 – 2415   *** p =  .6545 p =  .2297 p =  .1867 p =  .2105 p =  .3476   ****   * p =  .2323   *
 +  1646
ER(IHC)
 – 551 ****   **** **** **   **** **** *   *** p =  .2564 ****
 +  3911        
PR(IHC)
 – 828 ****   **** **** p =  .2212   **** * p =  .1015 p =  .4141 p =  .4587 ****
 +  3498       
HER2(IHC)
 – 3582   **** ****   **** p =  .4834 **** **** p =  .5320 p =  .2814 ****   ****
 +  661       
Basal-like statues
 Basal-like 832 ****   ** **** ***   **** **** p =  .2002   *** * ****
 Not 3836        
Triple-negative statues(IHC)
 TNBC 317 ****   **** **** p =  .4260   **** **** *   ** p =  .7470 ****
 Not 4119        
P53 status (sequence-based)
 Wild type 699   **** ***   **** p =  .2017 ****   *** p =  .7978 p =  .6453 p =  .0796   ****
 Mutated 328    
SBR
 SBR1 544 SBR2 > SBR1 **** SBR3 < SBR1 **** SBR3 > SBR1 **** SBR3 > SBR1 **** SBR2 < SBR1 **** SBR2 < SBR1 **** SBR3 > SBR1 **** p =  .0730 SBR3 < SBR1 **** SBR2 > SBR1 ****
 SBR2 1699 SBR3 > SBR1 **** SBR3 < SBR2 **** SBR3 > SBR2 **** SBR3 > SBR2 **** SBR3 < SBR1 **** SBR3 < SBR1 **** SBR2 > SBR1 * SBR3 < SBR2 **** SBR3 > SBR1 ****
 SBR3 1374 SBR3 > SBR2 **** SBR2 = SBR1 SBR2 > SBR1 **** SBR2 > SBR1 ** SBR3 < SBR2 **** SBR3 < SBR2 ** SBR3 > SBR2 * SBR2 < SBR1 *** SBR3 > SBR2 ****
TPI
 NPI1 1173 NPI2 > NPI1 **** NPI2 < NPI1 * NPI2 > NPI1 **** NPI2 > NPI1 **** NPI2 < NPI1 **** NPI2 < NPI1 **** NPI3 > NPI1 **** NPI3 > NPI1 * NPI2 < NPI1 **** NPI2 > NPI1 ****
 NPI2 1525 NPI3 > NPI1 **** NPI3 < NPI1 * NPI3 > NPI1 **** NPI3 > NPI1 **** NPI3 < NPI1 **** NPI3 < NPI1 **** NPI3 > NPI2 ** NPI2 = NPI1 NPI3 < NPI1 **** NPI3 > NPI1 ****
 NPI3 416 NPI3 > NPI2 **** NPI3 = NPI2 NPI3 > NPI2 ** NPI3 > NPI2 * NPI3 = NPI2 NPI3 = NPI2 NPI2 > NPI1 * NPI3 = NPI2 NPI3 < NPI2 ** NPI3 > NPI2 ***
  1. ↑, upregulated; –, no significant difference; No., number of patients enrolled; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; IHC, immunohistochemistry; SBR, Scarff-Bloom-Richardson grade; NPI, Nottingham prognostic index
  2. *P < 0.05; **P < 0.01; *** P < 0.001; ****P < 0.0001